Recent studies have identified several polymorphisms in the human insulin receptor substrate-1 (IRS-1) gene. The most prevalent IRS-1 variant, a Gly→Arg change at the codon 972, has been reported to be increased in prevalence among patients with type 2 diabetes. Carriers of the Arg 972 substitution are characterized by lower fasting insulin and C-peptide levels compared with non-carriers, suggesting that the Arg 972 IRS-1 variant may contribute to impairment of insulin secretion. In this study, we stably overexpressed both wild-type IRS-1 (RIN-WT) and Arg 972 IRS-1 variant (RIN-Arg 972 ) in RIN β cells to investigate directly whether the polymorphism in codon 972 of IRS-1 impairs insulin secretion. The Arg 972 IRS-1 variant did not affect expression or function of endogenous IRS-2. RIN-WT showed a marked increase in both glucose-and insulin-stimulated tyrosine phosphorylation of IRS-1 compared with control RIN cells. The Arg 972 IRS-1 variant did not alter the extent of either glucoseor insulin-stimulated tyrosine phosphorylation of recombinant IRS-1. However, RIN-Arg 972 showed a significant decrease in binding of the p85 subunit of phosphatidylinositol-3-kinase (PI 3-kinase) with IRS-1, compared with RIN-WT. Compared with control RIN cells, insulin content was reduced to the same extent in RIN-WT or RIN-Arg 972 at both the protein and mRNA levels. Both glucose-and sulfonylurea-induced insulin secretion was increased in RIN-WT compared with control RIN cells. By contrast, RIN cells expressing Arg 972 IRS-1 exhibited a marked decrease in both glucose-and sulfonylurea-stimulated insulin secretion compared with RIN-WT. These data suggest that the insulin signaling pathway involving the IRS-1/PI 3-kinase may play an important role in the insulin secretory process in pancreatic β cells. More importantly, the results suggest that the common Arg 972 IRS-1 polymorphism may impair glucose-stimulated insulin secretion, thus contributing to the relative insulin deficiency observed in carriers of this variant.
major substrates of the insulin receptor are insulin receptor substrates 1 and 2 (IRS-1 and IRS-2) (13) (14) (15) . IRS molecules are rapidly tyrosine phosphorylated after insulin stimulation and serve as multisite docking proteins for various effector molecules possessing src homology 2 (SH2) domains, including phosphatidylinositol-3-kinase (PI 3-kinase) (15) . IRS-1 was the first characterized substrate. IRS-1 is ubiquitously expressed in tissues that are responsible for glucose production, glucose uptake, and insulin productionsuch as liver, skeletal muscle, and pancreatic β cells (15) (16) (17) -and is thought to play a major role in mediating both metabolic and mitogenic effects of insulin (18, 19) . Molecular scanning of the IRS-1 gene in normal individuals and patients with type 2 diabetes has revealed several polymorphisms resulting in amino acid substitutions (20) (21) (22) (23) (24) , the most common of which is a Gly→Arg substitution at codon 972 (Arg 972 ). According to available data, the Arg 972 polymorphism is twice as prevalent in patients with type 2 diabetes as in control subjects. Transfection studies have shown that the Arg 972 polymorphism impairs insulin-stimulated signaling via the PI 3-kinase pathway (25, 26) . These data suggest that the Arg 972 IRS-1 variant may contribute to the development of type 2 diabetes. Carriers of the Arg 972 IRS-1 variant are characterized by low fasting plasma concentrations of insulin and C-peptide (20) . A young, healthy, lean male homozygous for the Arg 972 variant had low fasting plasma insulin levels and a low acute insulin response (22) . In addition, it has been reported that glucose-tolerant offspring of patients with type 2 diabetes who carry the Arg 972 IRS-1 variant are characterized by lower fasting plasma insulin levels and a lower insulin response to an oral glucose load compared with non-carriers (27) . It has been shown that glucose-stimulated insulin secretion may be modulated by autocrine activation of the insulin signal-transduction pathway involving insulin receptor phosphorylation, tyrosine phosphorylation of IRS-1, and activation of PI 3-kinase (17, 28) . Taken together, these data raise the intriguing hypothesis that a single molecular defect in insulin signaling, involving the defective interaction between IRS-1 and PI 3-kinase, might result in both peripheral insulin resistance and impaired insulin secretion. To address this issue, we overexpressed both wild-type IRS-1 and Arg 972 IRS-1 variant in RIN β cells, and measured glucose-stimulated insulin secretion. Data obtained showed that in β cells expressing the Arg 972 IRS-1 variant, insulin secretion stimulated by glucose is impaired compared with β cells expressing wild-type IRS-1, thus suggesting that this polymorphism may compromise the ability of β cells to compensate for insulin resistance.
Methods
Reagents. Hybond-P PVDF transfer membranes, protein A-Sepharose, and all radiochemicals were from Amersham Pharmacia Biotech (Milan, Italy). Geneticin G-418 sulphate, Lipofectamine transfection reagent, media, and FCS for cell culture were from GIBCO BRL (Grand Island, New York, USA). Glybenclamide was from Guidotti Laboratory (Pisa, Italy). SDS-PAGE and Western blot reagents were from Bio-Rad Laboratories Inc. (Richmond, California, USA). Anti-IRS-1, anti-IRS-2, and anti-rat PI 3-kinase polyclonal antibodies were purchased from Upstate Biotechnology Inc. (Lake Placid, New York, USA). Anti-phosphotyrosine polyclonal antibody was from Transduction Laboratories (Lexington, Kentucky, USA). Enhanced chemiluminescence reagent detection system (SuperSignal CL-HRP Substrate System) was from Pierce Chemical Co. (Rockford, Illinois, USA). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA).
Cell cultures. RIN 1046-38 cells were subcultured weekly in M199 medium supplemented with 10% FCS, and were used at passages 16-25, at which they maintain a glucose responsivity in the range of 0.1-2.8 mM (29) .
Generation of human IRS-1 cDNAs. A fragment of human genomic DNA containing the entire coding sequence of IRS-1 was cloned and ligated into pcDNA3 expression vector (pcDNA3-WT-IRS-1) as previously described (18) . The cDNA construct containing the Arg 972 substitution was generated by site-directed mutagenesis by overlap extension using PCR. Wild-type IRS-1 was used as template for PCR-mediated oligonucleotide-directed mutagenesis. The PCR fragment containing the codon 972 variant of IRS-1 was digested with BamHI and NheI restriction endonucleases and inserted into pcDNA3-WT-IRS-1 that had been previously digested with the same enzymes. The presence of the substitution and the entire sequence of the fragment inserted was confirmed by nucleotide sequencing.
Transfection of IRS-1 cDNAs. RIN cells were seeded at a density of 2 × 10 5 cells/mL, treated for 4 hours with transfection medium containing 2 µg pcDNA3 alone, pcDNA3-WT-IRS-1, or mutant IRS-1 (pcDNA3-Arg 972 -IRS-1), and suspended with 15 µL Lipofectamine in 1 mL serum-free M199. One milliliter of M199 supplemented with 10% FCS was then added to the transfection mixture, according to the manufacturer's instructions.(GIBCO BRL). After 24 hours, the medium was replaced with M199 supplemented with 10% FCS, and the cells were incubated for a further 72 hours. Thereafter, the cells were incubated with selective medium containing 0.4 mg/mL geneticin G-418 sulfate. Individual G-418-resistant clones were collected and lysed for 30 minutes in buffer containing 50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, and 1% Triton X-100. Insoluble material was removed by centrifugation in microfuge for 10 minutes, and the supernatant was stored for Western blot analysis. Protein content of each sample was determined by Bradford assay using BSA as standard.
Tyrosine phosphorylation of IRS-1 and IRS-2, and association of IRS-1 and IRS-2 with the p85 subunit of PI 3-kinase.
RIN cells cultured in 100-mm-diameter dishes were washed 3 times with glucose-free buffer A containing 114 mM NaCl, 25.5 mM NaHCO 3 , 10 mM HEPES, 2.5 mM CaCl 2 , 4.7 mM KCl, 1.21 mM KH 2 PO 4 , 1.16 mM MgSO 4 , and 0.1% BSA (pH 7.4). Thereafter, the cells were incubated in the presence or absence of maximally stimulating concentrations of glucose (2.8 mM) or insulin (100 nM) for the indicated period of time. At the end of incubation, cells were washed with ice-cold PBS and lysed for 45 minutes at 4°C in lysis buffer containing 20 mM Tris-HCL (pH 7.6), 137 mM NaCl, 2 mM EDTA, 10 mM NaPP, 2 mM Na 3 VO 4 , 10 mM NaF, 8 µg/mL leupeptin, 2 mM phenylmethylsulfonylfluoride, 10% glycerol, and 1.5% NP-40. Insoluble material was removed by centrifugation in microfuge for 5 minutes, and the supernatant was saved for analysis by immunoprecipitation and Western blotting.
Immunoprecipitation and Western blotting. Cell lysates were incubated for 16 hours at 4°C with anti-IRS-1 antibody (4 µg for 1 mg of cell lysate) or anti-IRS-2 antibody (1:1,000). Immunocomplexes were collected by incubation with protein A-Sepharose for 2 hours at 4°C. Immunoprecipitates proteins were washed 3 times with wash buffer containing 150 mM NaCl, 10 mM Tris (pH 7.8), 1.5% NP-40, 1 mM Na 3 VO 4 , and 1 mM phenylmethylsulfonylfluoride; they were then resuspended in Laemmli buffer. Equal amounts of cell lysates or immunoprecipitated proteins were subjected to SDS-PAGE under reducing conditions. Proteins resolved by SDS-PAGE were electrophoretically transferred to nitrocellulose membrane. The filters were then incubated for 16 hours at 4°C with the indicated primary antibodies, followed by incubation with peroxidase-conjugated goat anti-rabbit antibodies. Proteins were detected by using enhanced chemiluminescence, and band densities were quantified by densitometry.
Insulin secretion. RIN cells were seeded in 24-multiwell plates at a density of 10 5 cells/mL. After 48 hours, the medium was removed, and the cells were washed twice for 30 minutes at 37°C with glucose-free buffer A. The cells were incubated in the presence or absence of increasing concentrations of glucose for different periods of time. To study sulfonylurea-induced insulin secretion, RIN cells were incubated for 30 minutes at 37°C in glucose-free buffer A in the presence or absence of different concentrations of Glybenclamide, a second-generation sulfonylurea. Aliquots of the supernatant were collected and stored at -20°C for subsequent insulin RIA. Cells were extracted overnight at 4°C with a solution of acidified ethanol for measurement of the intracellular insulin content. Insulin amount was determined by RIA.
Northern blot analysis of insulin mRNA expression. Total RNA was extracted from RIN cells using the acidguanidinium-thiocyanate-phenol-chloroform procedure (30) . Twenty micrograms of total RNA was heated at 65°C and applied to a 1% agarose gel containing 5% formaldehyde. RNAs were then blotted onto nylon membrane using a PosiBlot apparatus (Stratagene, La Jolla, California, USA) and cross-linked. The blots were hybridized with a 450-kb mouse insulin cDNA (kindly provided by A.L. Notkins, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland, USA) labeled with [α-32 P]dCTP by random priming procedure using 2 U of Klenow polymerase. Band densities were quantified by densitometry.
Statistics. Statistical analysis was carried out by 1-way ANOVA followed by nonpaired Student's t test. Data in figures are expressed as mean ± SE. P values less than 0.05 were considered significant. Intracellular insulin content and insulin mRNA level. In the basal glucose-free state, total intracellular insulin content measured by RIA was similar in RIN cells expressing both wild-type IRS-1 and Arg 972 IRS-1 variant. However, insulin content was significantly decreased in both RIN-WT and RIN-Arg 972 compared with control RIN cells (4.84 ± 0.46, 4.91 ± 0.40, and 6.58 ± 0.50 ng/10 5 cells for RIN-WT, RIN-Arg 972 , and RIN control cells, respectively; P < 0.05). To determine whether the decrease in insulin content in RIN cells expressing both wild-type IRS-1 and Arg 972 IRS-1 variant was due to changes in their insulin mRNA levels, total RNA was extracted from each cell line, and insulin mRNA expression was analyzed by Northern blot. A 450-kb mouse insulin cDNA labeled with [α-32 P]dCTP was used as probe, and a GAPDH cDNA probe was used as control to ensure equal RNA loading. As shown in Figure 4 , overexpression of both wild-type IRS-1 and Arg 972 IRS-1 in RIN cells results in a similar decrease in insulin mRNA levels compared with control RIN cells.
Results

Expression of recombinant IRS-1 in RIN cells
Glucose-stimulated insulin secretion. Time course of glucose-stimulated insulin secretion revealed that maximal increase was reached after 30 minutes of incuba-
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Figure 2
Glucose-and insulin-stimulated tyrosine phosphorylation of IRS-1, and association with p85 subunit of PI 3-kinase in RIN β cells expressing wild-type IRS-1 and Arg 972 IRS-1. RIN-WT and RIN-Arg 972 cells were incubated in the presence or absence of 2.8 mM glucose for 0, 2, and 10 minutes, or in the presence or absence of 100 nM insulin for 2 minutes, at 37°C. The cells were then lysed, and equal amounts of total proteins were immunoprecipitated (IP) with anti-IRS-1 antibody, subjected to SDS-PAGE, and Western immunoblotted (WB) with either anti-phosphotyrosine antibody (top) or anti-p85 antibody (bottom). Proteins were detected by using enhanced chemiluminescence, and band densities were quantified by densitometry. The autoradiographs shown are representative of 3 independent experiments.
Figure 3
Glucose-and insulin-stimulated tyrosine phosphorylation of endogenous IRS-2, and association with p85 subunit of PI 3-kinase in RIN β cells expressing wild-type IRS-1 and Arg 972 IRS-1. RIN-WT and RINArg 972 cells were incubated in the presence or absence of 2.8 mM glucose for 0, 2, and 10 minutes, or in the presence or absence of 100 nM insulin for 2 minutes, at 37°C. The cells were then lysed, and equal amounts of total proteins were immunoprecipitated (IP) with anti-IRS-2 antibody, subjected to SDS-PAGE, and Western immunoblotted (WB) with either anti-phosphotyrosine antibody (top) or anti-p85 antibody (bottom). Proteins were detected by using enhanced chemiluminescence, and band densities were quantified by densitometry. The autoradiographs shown are representative of 3 independent experiments.
tion in all cell lines ( Figure 5 Figure 6 ). By contrast, expression of the Arg 972 IRS-1 variant in RIN cells caused a significant reduction in glucosedependent insulin secretion compared with RIN cells expressing wild-type IRS-1 (Figure 6a ). At 0.1 mM, glucose induced a 75 ± 12 and 33 ± 2% increase in insulin release above the basal values (P < 0.005), and at 2.8 mM, glucose induced a 120 ± 14 and 50 ± 5% increase (P < 0.01), in RIN cells expressing wild-type IRS-1 and Arg 972 IRS-1, respectively (Figure 6b ). Sulfonylurea-induced insulin secretion. To determine whether the Arg 972 IRS-1 variant impairs the response to other secretagogues, we evaluated the effects of Glybenclamide, a second-generation sulfonylurea. Sulfonylureas stimulate insulin release from pancreatic β cells through the interaction with a specific plasma membrane receptor coupled to the ATP-dependent K + channel, leading to its closure. As a consequence of the inhibition of K + efflux, β cells depolarize, inducing Ca 2+ entry, which in turn stimulates extrusion of insulin granules. Expression of wild-type IRS-1 in RIN cells resulted in a significant increase in Glybenclamideinduced insulin secretion compared with control RIN cells, at any concentrations of drug tested (Figure 7) . By contrast, expression of the Arg 972 IRS-1 variant in RIN cells caused a significant reduction in Glybenclamidedependent insulin secretion compared with RIN cells expressing wild-type IRS-1 ( Figure 7 ).
Discussion
As a consequence of its extreme complexity, the regulation of insulin secretion from pancreatic β cells is still not completely clarified. Glucose is the principal stimulus for insulin secretion. Through its metabolism, glucose determines the closure of the ATPdependent K + channels, resulting in plasma membrane depolarization and influx of extracellular Ca 2+ into cytosol, which, in turn, triggers exocytosis of insulin granules. It has been shown that glucoseinduced insulin secretion activates, via an autocrine loop, the β-cell surface insulin receptor tyrosine kinase and its downstream signal-transduction pathway involving tyrosine phosphorylation of IRS-1 and activation of PI 3-kinase (17, 28) . IRS-1 is a major intracellular substrate of the insulin receptor in most insulin-sensitive tissues, and has been considered a plausible candidate gene for type 2 diabetes. The IRS-1 gene is highly polymorphic, with coding sequence variations in about 5% of normal subjects and in 10-20% of patients with type 2 diabetes. The most prevalent polymorphism is a Gly→Arg substitution at codon 972 (Arg 972 ) of the IRS-1 gene, and its overall frequency is increased in type 2 diabetic patients compared with normal individuals (10.7 vs. 5.8%, respectively; P < 0.02). Normal and diabetic subjects heterozygous for the Arg 972 variant exhibited both low fasting plasma insulin and C-peptide levels (20) . In addition, nondiabetic first-degree relatives of patients with type 2 diabetes who are heterozygous for the Arg 972 variant exhibited both a lower fasting plasma insulin level and a lower insulin response to an oral glucose load when compared with non-carriers (27) atic β-cell insulin secretion, thus contributing to the development of type 2 diabetes. In this study, we stably transfected RIN 1046-38 β cells with either wildtype IRS-1 or Arg 972 IRS-1 variant to investigate directly whether this amino acid substitution impairs β-cell function. As noted above, it has been shown that glucose induces tyrosine phosphorylation of the insulin receptor and IRS-1, via an autocrine loop of the exocytosed insulin. We therefore determined both glucose-and insulin-induced tyrosine phosphorylation of the insulin receptor and IRS-1. Both glucose and insulin stimulated tyrosine phosphorylation of the insulin receptor and IRS-1 in control RIN cells, consistent with previous studies performed in a different insulinoma cell line (17) and in rat pancreatic islets (28) . RIN cells overexpressing wild-type IRS-1 showed a marked increase in both glucose-and insulin-stimulated tyrosine phosphorylation of IRS- 
Figure 7
Fractional insulin secretion in response to Glybenclamide. Control RIN, RIN-WT, and RIN-Arg 972 cells were incubated in glucose-free buffer in the presence or absence of increasing concentration of Glybenclamide. At the end of incubation, total cellular insulin content was extracted into acidified ethanol, and aliquots of the supernatant were collected. Insulin concentration in both cellular extracts and supernatant was determined by RIA. The amount of secreted insulin was normalized by the total insulin content. The results are expressed as the percentage of fractional insulin secretion above basal and are the mean ± SE of 4 independent experiments, each carried out in triplicate. *P < 0.05. In an attempt to elucidate whether the Arg 972 IRS-1 variant impairs insulin secretion induced by secretagogues other than glucose, we examined the effect of Glybenclamide, a second-generation sulfonylurea. RIN cells expressing wild-type IRS-1 showed a marked increase in sulfonylurea-stimulated insulin secretion compared with control RIN cells. By contrast, RIN cells expressing Arg 972 IRS-1 exhibited a significant decrease in sulfonylurea-stimulated insulin secretion compared with RIN cells expressing wild-type IRS-1, similar to data obtained using glucose. These data raise the intriguing hypothesis that subjects carrying the Arg 972 IRS-1 variant may have an altered response to these drugs. Further in vivo studies are necessary to elucidate this issue.
To our knowledge, this is the first study to demonstrate the functional impact of a naturally occurring IRS-1 polymorphism on insulin secretion by pancreatic β cell. The Arg 972 IRS-1 variant is more prevalent in subjects with type 2 diabetes who have insulin resistance associated or not with dyslipidemia (24) . Equilibrium glucose infusion rates during a euglycemic clamp in normal and type 2 diabetic subjects with the Arg 972 polymorphism are decreased compared with those in comparable groups without polymorphism (23) . In obese nondiabetic subjects, the Arg 972 polymorphism of IRS-1 in its heterozygous form is associated with a 50% reduction in insulin sensitivity compared with obese subjects without polymorphism (22) . We have recently observed that expression of the Arg 972 IRS-1 variant in L6 skeletal muscle cells causes an impairment in glucose transport due to a defect in translocation of glucose transporters GLUT1 and GLUT4 to the plasma membrane (ref. 36 ; and M.L.
Hribal et al, manuscript submitted for publication). These observations suggest that the Arg 972 polymorphism of IRS-1 might contribute to insulin resistance as well. Taken together with the results of the present investigation, we suggest that amino acid substitution at codon 972 of IRS-1 may represent the first identified defect of a single gene involved in insulin signaling, resulting in both peripheral insulin resistance and impaired insulin secretion, the 2 key components in the pathogenesis of type 2 diabetes.
